Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4.

Cyclin E-CDK2 influences cancer cell transcription and immunotherapy response by phosphorylating BRD4, with overactivation promoting resistance and inhibition enhancing immune therapy efficacy.

• Why it matters: Understanding how cell-cycle regulators like cyclin E-CDK2 affect cancer transcription and immune response can improve therapeutic strategies, especially since hyperactivation is common in tumors.
• What they did: The study used molecular and cellular approaches to show that CDK2 phosphorylates BRD4, altering its chromatin binding, and that manipulating cyclin E-CDK2 levels impacts gene expression, immune evasion, and therapy resistance in cancer cells.
• The result: Inhibiting CDK2 boosts immune infiltration and enhances checkpoint blockade effectiveness, suggesting that targeting CDK2 could improve immunotherapy outcomes in cancers with cyclin E-CDK2 hyperactivation.